Search Results
Dec 06, 2025, 07:00 ET Research Reveals Avenues for Informing and Improving Sickle Cell Care
of exa-cel that are underway in children 5-11 years old. To date, the CLIMB THAL-141 trial has dosed 13 patients with beta-thalassemia, and the CLIMB SCD-151 trial has dosed 11 patients with sickle cell disease.In CLIMB THAL-141, six of 13 patients to date have been evaluated for the primary endpoint
More news about: American Society of Hematology
Dec 04, 2025, 12:20 ET Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
our programs and the expanding body of clinical and preclinical data reinforcing the strength of our AML-focused pipeline," said Angelos Stergiou, MD, ScD h.c., President and CEO of SELLAS. "The Phase 3 REGAL trial of GPS is advancing as planned as highlighted by the key opinion leaders at our recent
More news about: USA News Group
Dec 04, 2025, 08:30 ET Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium
#PS2-10-25Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CSTMetabolic and Immune Reprogramming via SCD1 Inhibition Enhances Chemo-Immunotherapy Response in TNBC. #PS2-12-07Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CSTImmune
More news about: Caris Life Sciences
Dec 03, 2025, 08:15 ET Novel Transdermal Curcumin (VAS-101) Improves Cardiac Mitochondrial Function in Sickle Cell Disease Mouse Model, New FDA Led Study Shows
validated SCD model.Proteomic normalization: VAS‑101 reversed or mitigated abnormalities in mitochondrial proteins involved in β‑oxidation, glycolysis, membrane dynamics, calcium handling, and mitophagy, indicating broad mitochondrial protective effects in this validated SCD model.Dr.
More news about: Vascarta Inc
Dec 02, 2025, 07:09 ET American Liver Foundation Hosts the 34th Annual Irwin M. Arias Symposium
Taken": My Unusual Path from Chemical Engineering to Nanotechnology to Advances in Biology and Medicine Robert Langer, ScD, Massachusetts Institute of Technology For the
More news about: American Liver Foundation
Nov 24, 2025, 07:00 ET BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
plerixafor.A second SCD study, sponsored by St. Jude Children's Research Hospital, continues to enroll patients. The study is a multi-center Phase 1 clinical trial evaluating motixafortide for the mobilization of CD34+ HSCs used in the development of gene therapies for patients with SCD.APHEXDA
More news about: BioLineRx Ltd.
Nov 21, 2025, 12:39 ET Hackensack Meridian John Theurer Cancer Center Unveils Research at the 67th American Society of Hematology Annual Meeting
Blood DisordersReduced intensity haploidentical bone marrow transplantation in children with severe sickle cell disease (SCD): BMT CTN 1507 (ABSTRACT 25-11982) End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs.
More news about: Hackensack Meridian John Theurer Cancer Center
Nov 19, 2025, 09:00 ET ToolGen Completes U.S. Patent Registration for Core CRISPR Cas9 RNP Technology; Files U.S. Lawsuit Related to CASGEVY®
CASGEVY®. CASGEVY® is the first approved CRISPR-based genome-editing therapy and is indicated for patients with sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). It has received approvals and has been commercialized in major regions, including the U.S. and Europe.
More news about: ToolGen
Nov 18, 2025, 09:00 ET The Galien Foundation Announces 2025 Prix Galien Bridges Awards Nominees for "Best Bridge-Builder Institution," "Best Biomedical Product," "Best Medical Technology/AI Advances in Human Health," "Best Product for Rare/Orphan Diseases," and "Best Public Sector Innovation"
Grifols sCD38
More news about: The Galien Foundation
Nov 18, 2025, 08:30 ET Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
Baharaff, President and CEO of Galmed Pharmaceuticals commented: "Aramchol is the most advanced down regulator of SCD-1 (Stearoyl – CoA desaturase) in clinical development. Inhibition of SCD-1 has been recently investigated in multiple indications, re-emphasizing its metabolic master switch potential and
More news about: Galmed Pharmaceuticals Ltd.
Nov 18, 2025, 07:32 ET Medunik USA reaffirms support for Sickle Cell Disease community with uninterrupted supply and Patient-Centered Services
its flagship product for sickle cell disease (SCD): Siklos® (hydroxyurea). As access to certain hydroxyurea products may be constrained, patients and healthcare providers can continue to rely on Siklos® to help safeguard continuity of care for people with SCD treated with hydroxyurea.
More news about: Medunik USA
Nov 14, 2025, 15:57 ET Emmaus Life Sciences Reports Quarterly Financial Results
About Sickle Cell DiseaseThere are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally. The sickle gene is found in every ethnic group, not just among those of African descent; and in the
More news about: Emmaus Life Sciences, Inc.
Nov 03, 2025, 14:23 ET Vascarta Inc: Transdermal Curcumin (VAS-101 Drug Candidate) Interrupts the Neuroinflammatory Pathophysiological Cascade Associated with Acute Sickle Cell Crisis
leading to oxidative stress and mitochondrial dysfunction in sensory neurons. VAS-101 interrupts this SCD pathophysiological cascade, suggestive of a preventive effect on acute pain episodes in SCD. Together these results have positive implications for a transdermal treatment to
More news about: Vascarta Inc
Oct 28, 2025, 06:07 ET Distinct Brain Features in Football Players May Tell Who Is at Risk of Long-Term Traumatic Disease
Clinic in Arizona in Scottsdale; Charles Bernick, MD, MPH, at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas; Jeffrey Cummings, MD, ScD, at the University of Nevada, Las Vegas; Sylvain Bouix, PhD, at the Universite du Quebec in Montreal; and study co-senior investigator Inga Koerte, MD,
More news about: NYU Langone Health System
Oct 22, 2025, 08:30 ET The Evolution of Precision Medicine in Age-Related Neurological Diseases, Upcoming Webinar Hosted by Xtalks
PPD clinical research business of Thermo Fisher Scientific, Panos Papanastasopoulos, Associate Medical Director; Debra Schaumberg, ScD, OD, MPH, Vice President & Global Head, Strategic Development and Global Head of Strategic Scientific Solutions for Ophthalmology; Chair, Research
More news about: Xtalks
Oct 21, 2025, 10:00 ET Lupus Foundation of America Research Showcased at 2025 American College of Rheumatology Annual Meeting
Modulation in Lupus: Antigen-Driven Expansion as a Protective Strategy Alicia Tran (student of Linda Hiraki, MD, ScD, 2023 Pediatric Lupus Research Grant awardee) -
More news about: Lupus Foundation of America, Inc.
Oct 20, 2025, 02:37 ET Immunotherapy After Surgery Shows Promise in Treating Rare, Aggressive Skin Cancer
NCI's National Clinical Trials Network, and NCI grant R50CA282100. Besides Mehnert, other study co-investigators are Sandra Lee, ScD, and David Miller, MD, PhD, at the Dana-Farber Cancer Institute in Boston; Brian Gastman, MD, and Donald Eicher, MD, at the Cleveland Clinic; Charles
More news about: NYU Langone Health System
Oct 15, 2025, 22:36 ET A Supermicro apresenta uma nova linha de soluções empresariais, Data Center Building Block Solutions, para infraestruturas de data center e serviços de gerenciamento
IA e observabilidade integrada, capacitando as equipes a mover-se do código ao modelo com maior rapidez e segurança.O SuperCloud Director (SCD) oferece controle de nuvem de IA multilocatário com computação bare metal integrada, rede Ethernet e InfiniBand e várias plataformas de armazenamento.
More news about: Super Micro Computer, Inc.
Oct 15, 2025, 22:28 ET Supermicro introduceert Data Center Building Block Solutions, een nieuwe businesslijn voor apparatuur en beheerdiensten voor datacenters
gebaseerde workflows en ingebouwde observeerbaarheid, waardoor teams sneller en veiliger van code naar model kunnen gaan.SuperCloud Director (SCD) biedt multi-tenant AI-cloudbeheer met geïntegreerde bare metal Compute, Ethernet & InfiniBand-netwerk en meerdere opslagplatformen.
More news about: Super Micro Computer, Inc.
Oct 14, 2025, 09:05 ET Supermicro Introduces New Business Line, Data Center Building Block Solutions, for Data Center Facilities Equipment and Management Services
provisioning, AI-native workflows, and built-in observability, empowering teams to go from code to model faster and safer.SuperCloud Director (SCD) offers multi-tenant AI cloud control with integrated bare metal Compute, Ethernet & InfiniBand network, and multiple storage platforms.
More news about: Super Micro Computer, Inc.
Oct 14, 2025, 09:05 ET Supermicro Introduces New Business Line, Data Center Building Block Solutions, for Data Center Facilities Equipment and Management Services
provisioning, AI-native workflows, and built-in observability, empowering teams to go from code to model faster and safer.SuperCloud Director (SCD) offers multi-tenant AI cloud control with integrated bare metal Compute, Ethernet & InfiniBand network, and multiple storage platforms.
More news about: Super Micro Computer, Inc.
Oct 09, 2025, 09:06 ET New JNCCN Study Confirms it's 'Never Too Late' to See Survival Benefits from Quitting Smoking--Even With Late-Stage Cancer
care." "It is never too late, and no one is ever 'too sick' to quit smoking," added senior author Li-Shiun Chen, MD, MPH, ScD, Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine. "Our study found that individuals with cancer who stop smoking after
More news about: National Comprehensive Cancer Network
Oct 07, 2025, 20:00 ET Trailblazing Young Scientists Honored with $250,000 Prizes at Blavatnik National Awards Gala
made at a black-tie gala, held this evening at the American Museum of Natural History, hosted by Len and Emily Blavatnik and presented by Subra Suresh, ScD, Former Director of the National Science Foundation and current President of the Global Learning Council in Switzerland. In his opening remarks, Dr.
More news about: The Blavatnik Family Foundation; The New York Academy of Sciences
Oct 07, 2025, 11:00 ET Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care
Recent FDA approvals and ongoing clinical trials for Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), and sickle cell disease (SCD) are redefining treatment paradigms. By 2033, gene therapies are expected to account for nearly 30% of market revenues.
More news about: DataM Intelligence 4 Market Research LLP
Oct 07, 2025, 05:30 ET Cardinal Health launches a new all-in-one solution for deep vein thrombosis and pulmonary embolism prevention
© [2025] Cardinal Health. All Rights Reserved. CARDINAL HEALTH, the CARDINAL HEALTH LOGO, KENDALL SCD SMARTFLOW, KENDALL SCD, and PATIENT SENSING are trademarks of Cardinal Health and may be registered in the US and/or in other countries .
More news about: Cardinal Health